Financial giants have made a conspicuous bearish move on Alnylam Pharmaceuticals. Our analysis of options history for Alnylam Pharmaceuticals ALNY revealed 11 unusual trades.
Delving into the details, we found 27% of traders were bullish, while 45% showed bearish tendencies. Out of all the trades we spotted, 9 were puts, with a value of $515,770, and 2 were calls, valued at $88,650.
Projected Price Targets
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $210.0 to $290.0 for Alnylam Pharmaceuticals during the past quarter.
Volume & Open Interest Trends
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Alnylam Pharmaceuticals's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Alnylam Pharmaceuticals's significant trades, within a strike price range of $210.0 to $290.0, over the past month.
Alnylam Pharmaceuticals Option Volume And Open Interest Over Last 30 Days
Significant Options Trades Detected:
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ALNY | PUT | SWEEP | BEARISH | 12/20/24 | $15.5 | $15.5 | $15.5 | $240.00 | $130.2K | 517 | 100 |
| ALNY | PUT | SWEEP | BEARISH | 12/20/24 | $3.5 | $3.0 | $3.5 | $210.00 | $62.6K | 170 | 457 |
| ALNY | PUT | TRADE | NEUTRAL | 12/20/24 | $58.5 | $55.9 | $57.0 | $290.00 | $57.0K | 241 | 40 |
| ALNY | CALL | TRADE | BULLISH | 01/15/27 | $54.0 | $50.5 | $54.0 | $250.00 | $54.0K | 0 | 10 |
| ALNY | PUT | TRADE | NEUTRAL | 12/20/24 | $50.1 | $46.6 | $48.1 | $280.00 | $52.9K | 395 | 11 |
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.
In light of the recent options history for Alnylam Pharmaceuticals, it's now appropriate to focus on the company itself. We aim to explore its current performance.
Alnylam Pharmaceuticals's Current Market Status
- With a volume of 446,657, the price of ALNY is up 0.74% at $233.99.
- RSI indicators hint that the underlying stock may be oversold.
- Next earnings are expected to be released in 86 days.
What Analysts Are Saying About Alnylam Pharmaceuticals
A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $350.2.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. Click here for access. * Maintaining their stance, an analyst from Canaccord Genuity continues to hold a Buy rating for Alnylam Pharmaceuticals, targeting a price of $384. * An analyst from Piper Sandler downgraded its action to Overweight with a price target of $296. * An analyst from HC Wainwright & Co. downgraded its action to Buy with a price target of $400. * An analyst from RBC Capital has revised its rating downward to Outperform, adjusting the price target to $300. * An analyst from TD Cowen persists with their Buy rating on Alnylam Pharmaceuticals, maintaining a target price of $371.
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Alnylam Pharmaceuticals, Benzinga Pro gives you real-time options trades alerts.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
